A Bayesian Approach to Residual Host Cell DNA Safety Assessment

References

1. 1.↵
   World Health Organization (WHO) Meeting Report. Study Group on Cell Substrates for Production of Biologicals. June 11–12, 2007; pp 1–30.
2. 2.↵
   1. Lewis A. M. Jr..,
   2. Krause P,
   3. Peden K.

   A defined-risks approach to the regulatory assessment of the use of neoplastic cells as substrates for viral vaccine manufacture. Dev. Biol. 2001, 106, 513–535.

   OpenUrl
3. 3.↵
   1. Petricciani J. C.,
   2. Regan P. J.

   Risk of neoplastic transformation from cellular DNA: calculations using the oncogene model. Dev. Biol. Stand. 1987, 68, 43–49.

   OpenUrlPubMed
4. 4.↵
   1. Petricianni J. C.,
   2. Horaud F. N.

   DNA, dragons and sanity. Biologicals 1995, 23 (3), 233–238.

   OpenUrlPubMed
5. 5.↵
   1. Petricciani J.,
   2. Loewer J.

   An overview of cell DNA issues. Dev. Biol. 2001, 106, 275–282.

   OpenUrl
6. 6.↵
   1. Sheng L.,
   2. Cai F.,
   3. Zhu Y.,
   4. Pal A.,
   5. Athanasiou M.,
   6. Orrison B.,
   7. Blair D. G.,
   8. Hughes S. H.,
   9. Coffin J. M.,
   10. Lewis A. M.,
   11. Peden K.

   Oncogenicity of DNA in vivo: tumor induction with expression plasmids for activated H-ras and c-myc. Biologicals 2008, 36 (3), 184–197.

   OpenUrlPubMed
7. 7.↵
   1. Peden K.,
   2. Sheng L.,
   3. Pal A.,
   4. Lewis A.

   Biological activity of residual cell substrate DNA. Dev. Biol. (Basel) 2006, 123, 45–56; discussion 55–73.

   OpenUrlPubMed
8. 8.↵
   FDA Guidance for Industry: Characterization and Qualification of Cell Substrates and Other Biological Materials Used in the Production of Viral Vaccines for Infectious Disease Indications. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research, February 2010.
9. 9.↵
   1. Krause P. R.,
   2. Lewis A. M. Jr..

   Safety of viral DNA in biological products. Biologicals 2008, 36 (3), 184–197.

   OpenUrlPubMed
10. 10.↵
    1. Yang H.,
    2. Zhang L.,
    3. Galinski M.

    A probabilistic model for risk assessment of residual host cell DNA in biological products. Vaccine 2010, 28 (19), 3308–3311.

    OpenUrlPubMed
11. 11.↵
    1. Yang H.

    Establishing acceptable limits of residual DNA. PDA J. Pharm. Sci. Technol. 2013, 67 (2), 155–163.

    OpenUrlAbstract/FREE Full Text
12. 12.↵
    R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria, 2015. URL: http://www.R-project.org/